A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
== Sources == Bulletins of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom Savinkov, Boris. The Fight Against the Bolsheviks // Russian Foreign Literature. Anthology in Six Volumes. Moscow: Kniga, 1990. Vol. 1, Book 2. The Union for the Defense of the Homeland and Freedom and the Yaroslavl Rebellion of 1918 // Proletarian Revolution, 1923, no. 10. Klementyev, V. F. In Bolshevik Moscow (1918–1920). Moscow: Russkiy Put, 1998. Korovin, V. V.; Rusanov, E. P. Boris Savinkov's Case // History of the Soviet Union, 1967, no. 6, pp. 143–155. Golinkov, D. L. The Collapse of the Enemy Underground. Moscow, 1971. Gopper, Karl. Four Collapses: Memoirs of General Gopper. Riga, 1920. Jekabsons, E.; Ščerbinskis, V. Participation of Latvians in White Military Forces During the Russian Civil War 1917–1920. Riga: Journal of the Latvian Institute of History, 1997. Shentalinsky, Vitaly. "His Among His Own. Savinkov in the Lubyanka." New World, no. 7 (1996).
44 (Rhodesia) Squadron, based in Lincolnshire on the east coast, was a heavy bomber unit, and part of No. 5 Group in RAF Bomber Command's front line. Unlike the other two squadrons designated as "Rhodesian", No. 44 Squadron never had a Rhodesian majority, despite efforts to so populate it. Initially equipped with Hampdens, it became the first RAF squadron to convert to Lancasters at the end of 1941. It played a prominent part in the attack on the MAN diesel factory at Augsburg in April 1942. In March 1943 No. 44 Squadron took part in the Allied bombing of cities in northern Italy, including Genoa and Milan, as well as targets in Germany such as Wilhelmshaven, Cologne and Berlin.
=== Coup trap === The accumulation of previous coups is a strong predictor of future coups, a phenomenon called the coup trap. A 2014 study of 18 Latin American countries found that the establishment of open political competition helps bring countries out of the coup trap and reduces cycles of political instability.
Ricin is very toxic if inhaled, injected, or ingested. It can also be toxic if dust contacts the eyes or if it is absorbed through damaged skin. It acts as a toxin by inhibiting protein synthesis. Ricin is resistant, but not impervious, to digestion by peptidases. By ingestion, the pathology of ricin is largely restricted to the gastrointestinal tract, where it may cause mucosal injuries. With appropriate treatment, most patients will make a good recovery.
Sources: en.wikipedia.org
Wells refused the offered freedom of the town, stating: "Bromley has not been particularly gracious to me nor I to Bromley and I don't think I want to add the freedom of Bromley to the freedom of the City of London and the freedom of the City of Brussels – both of which I have." He described Bromley in one of his novels as a "morbid sprawl of population".
== Research == In July 2020 scientists reported that they have observed a voltage-induced transformation of normally diamagnetic pyrite into a ferromagnetic material, which may lead to applications in devices such as solar cells or magnetic data storage. Researchers at Trinity College Dublin, Ireland have demonstrated that FeS2 can be exfoliated into few-layers just like other two-dimensional layered materials such as graphene by a simple liquid-phase exfoliation route. This is the first study to demonstrate the production of non-layered 2D-platelets from 3D bulk FeS2. Furthermore, they have used these 2D-platelets with 20% single walled carbon-nanotube as an anode material in lithium-ion batteries, reaching a capacity of 1000 mAh/g close to the theoretical capacity of FeS2. In 2021, a natural pyrite stone was crushed and pre-treated followed by liquid-phase exfoliation into two-dimensional nanosheets, which showed capacities of 1200 mAh/g as an anode in lithium-ion batteries.
The MEROPS online database for peptidases and their inhibitors: I04.953 Archived 2019-10-16 at the Wayback Machine Angiotensins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human AGT genome location and AGT gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P01019 (Angiotensin) at the PDBe-KB.
. This is a solution in a non-viscous gas (compressible fluid) whose density, velocities and pressure goes to zero far from the origin. (Note this is not a solution to the Clay Millennium problem because that refers to incompressible fluids where
== Notable people == Túpac Amaru II, revolutionary Angélica Mendoza de Ascarza, Peruvian human rights activist Kimberly Barzola, American community organizer and artist Benjamin Bratt, American actor Manco Cápac, Sapa Inca Luzmila Carpio, Bolivian musician Andrónico Rodríguez, Bolivian trade unionist and politician Martín Chambi, Peruvian photographer Renata Flores Rivera, Peruvian musician Oswaldo Guayasamín, Ecuadorian painter Ollanta Humala, former president of Peru Antauro Humala, Peruvian ethnocacerist Josh Keaton, American actor Q'orianka Kilcher, American actress Nancy Iza Moreno, Kichwa leader Leonidas Iza, Ecuadorian activist and Indigenous leader Delfín Quishpe, Ecuadorian musician and politician Tarcila Rivera Zea, Peruvian activist Izkia Siches, Chilean physician and politician Magaly Solier, Peruvian actress and musician Diego Quispe Tito, painter Francisco Tito Yupanqui, sculptor Alejandro Toledo, former president of Peru Edison Flores, Peruvian footballer Renato Tapia, Peruvian footballer Tania Pariona Tarqui, Peruvian politician
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.